More Older Women Find Fulfillment Staying Single
Wegovy and Foundayo offer new weight-loss pill options with key
Woman’s unexpected breast cancer battle reshapes life and priorities
October 13, 2026
Active Leader Confronts Arthritis, Loss of Mobility and Independence
October 11, 2026
Dermatology nurse helps patients beyond skin issues
October 10, 2026
Diet Key to Skin Health, Not Supplements Alone
October 8, 2026
Doctor Dispatches ❖ FEATURED
Processed foods can be nutritious-if chosen wisely
Doctor Dispatches ❖ FEATURED
Diabetes Care Evolves Over Decades
Doctor Dispatches ❖ FEATURED
Canada to overhaul outdated cancer screening guidelines
Doctor Dispatches ❖ FEATURED
Immunovant Launches Phase 3 Trial for Myasthenia Gravis Drug
Seniors Challenge Myths, Adopt Better Sex in Later Life
New study links air pollution, UV, humidity to migraine risk
New study reveals air pollution, UV, and humidity may significantly increase migraine risk, especially in late spring and summer.
October 22, 2026
Private Telehealth Expands Access for Canadian Patients
Private telehealth expands access for Canadian patients as Dr. Hance Clarke’s Toronto clinic provides 60-70% of visits virtually, cutting hours…
October 21, 2026
New study tests direct switch from IVIG to subcutaneous efgartigimod
New phase 4 study explores direct switch from IVIG to subcutaneous efgartigimod for CIDP patients without disease worsening, presented at…
October 2, 2026
New International Study Monitors Nipocalimab Use in Pregnancy
The PETUNIA study tracks nipocalimab pregnancy outcomes, monitoring pregnant people with myasthenia gravis, presented at the 2026 AANEM meeting.
October 1, 2026
FDA delays review of rare epilepsy drug
The FDA delays review of relutrigine, an experimental treatment for SCN2A/SCN8A-related epilepsy, pushing the decision date to December 27, 2026.
September 28, 2026
FDA approves first treatments for rare ataxia disorders
The FDA has approved the first treatments for rare ataxia disorders, including Omaveloxolone for Friedreich ataxia and levacetylleucine for ataxia-telangiectasi
September 26, 2026
Monocytes predict vaccine side effects
Dapagliflozin Reduces Heart Failure Risks, Regardless of Congestion
Sotatercept Added to PAH Treatment Guidelines
Wellness Rounds
Surgeon speaks out on mental health struggles
Wellness Rounds
Over 100 Arthritis Types Categorized by Cause
Wellness Rounds
Breast cancer patient redefines treatment with control and curiosity
Mother Cares for Daughter with Young-Onset Breast Cancer
A mother's journey caring for her daughter with young-onset breast cancer, navigating rare and complex cancer care for young adults…
October 14, 2026
No One Right Way to Feed Baby
Baby feeding choices with expert insights, recognizing there's no single right way to nourish your newborn effectively.
October 6, 2026
Trappsol Cyclo trial misses primary goal, subgroup benefits
Trappsol Cyclo trial missed primary goal in Niemann-Pick disease, but subgroup benefits show signs of slowing disease progression in a…
October 3, 2026
Latest News
Immunovant Launches Phase 3 Trial for Myasthenia Gravis Drug
Immunovant launches phase 3 trial for myasthenia gravis drug, testing imeroprubart in adults with generalized myasthenia gravis (gMG).
By Aliya Hassan October 5, 2026
Trappsol Cyclo trial misses primary goal, subgroup benefits
Trappsol Cyclo trial missed primary goal in Niemann-Pick disease, but subgroup benefits show signs of slowing disease progression…
By Nadia Yusof October 3, 2026
New study tests direct switch from IVIG to subcutaneous efgartigimod
New phase 4 study explores direct switch from IVIG to subcutaneous efgartigimod for CIDP patients without disease worsening,…
By Nadia Yusof October 2, 2026
New International Study Monitors Nipocalimab Use in Pregnancy
The PETUNIA study tracks nipocalimab pregnancy outcomes, monitoring pregnant people with myasthenia gravis, presented at the 2026 AANEM…
By Aliya Hassan October 1, 2026
FDA grants priority review to Genentech’s MS drug
The FDA granted priority review to fenebrutinib multiple sclerosis drug, an experimental BTK inhibitor that may treat relapsing…
By E Hughes September 30, 2026
Inebilizumab shows benefit in myasthenia gravis patients
Inebilizumab shows benefit in myasthenia gravis patients with sustained clinical progress.
By E Hughes September 29, 2026
FDA delays review of rare epilepsy drug
The FDA delays review of relutrigine, an experimental treatment for SCN2A/SCN8A-related epilepsy, pushing the decision date to December…
By E Hughes September 28, 2026
FDA approves first treatments for rare ataxia disorders
The FDA has approved the first treatments for rare ataxia disorders, including Omaveloxolone for Friedreich ataxia and levacetylleucine…
By Nadia Yusof September 26, 2026
Experts Offer Mentorship Advice for New Neurologists
Experts Blake Buletko and Galina Gheihman discuss neurologist mentorship advice for new doctors transitioning to practice. Explore essential…
By E Hughes September 25, 2026
FDA Grants Fast Track Status to Apitegromab
FDA grants fast track status to apitegromab for muscular dystrophy treatment, showing urgency in advancing new treatments.
By Aliya Hassan September 24, 2026